Short-term risk for AIDS-indicator diseases predicted by plasma HIV-1 RNA and CD4+lymphocytes

Citation
J. Romeu et al., Short-term risk for AIDS-indicator diseases predicted by plasma HIV-1 RNA and CD4+lymphocytes, SC J IN DIS, 31(1), 1999, pp. 37-42
Citations number
21
Categorie Soggetti
Clinical Immunolgy & Infectious Disease",Immunology
Journal title
SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES
ISSN journal
00365548 → ACNP
Volume
31
Issue
1
Year of publication
1999
Pages
37 - 42
Database
ISI
SICI code
0036-5548(1999)31:1<37:SRFADP>2.0.ZU;2-I
Abstract
The objective of this study was to assess the value of quantitative HIV-1 R NA as a predictor for the short-term risk of developing AIDS-defining event s in comparison with CD4 cell counts, A total of 1,028 samples from 324 pat ients mere analysed, Median initial CD? cell counts and HIV-1 RNA mere 249 x 10(6)/l (range 0-1400 x 10(6)/l) and 4.5 log copies/ml (range: 2.3-6.4 lo g copies/ml). CD4 cell counts and viral load (VL) values obtained the year before a single AIDS-indicator disease were selected to define the risk of developing that event. Cox regression models with CD4 cell counts and VL va lues treated as time-dependent covariates were performed to analyse the ris k for developing certain events. Receiver operating characteristic (ROC) cu rves mere used to compare CD4 cell counts and VL values as predictive marke rs for progression. During a median follow-up of 870 d (range 30-1381 d), 1 32 patients developed AIDS, Median log VL values during the year before the event were 3.6 for non-progressors and 5.2 for those who developed AIDS (p < 0.0001). Minimum log VL threshold values for developing diseases were 2. 3 for tuberculosis, 3.8 for Candida esophagitis, 4.4 for wasting syndrome, 4.5 for CMV disease and 4.7 for PCP, VL values mere not, however, a better predictive marker for developing specific events than were CD4 cell counts, Although we have identified VL thresholds for the risk of developing certa in AIDS-indicator diseases, the indication for starting prophylactic regime ns may still be based on CD4 cell counts.